P. Zuberbuhler

发表

Effects of positive end-expiratory pressure on oscillated volume during high frequency chest compression in children with cystic fibrosis.

C. Dosman, Richard L. Jones, P. Zuberbuhler, 2003, Canadian respiratory journal.

An in vitro method for determining regional dosages delivered by jet nebulizers.

W. Finlay, K. Stapleton, P. Zuberbuhler, 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

In vitro effect of a holding chamber on the mouth-throat deposition of QVAR (hydrofluoroalkane-beclomethasone dipropionate).

W. Finlay, C. Lange, P. Zuberbuhler, 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Newborn screening for cystic fibrosis in Alberta: Two years of experience.

M. Somerville, F. Bamforth, Stacey Hume, 2010, Paediatrics & child health.

Regional deposition of inhaled hygroscopic aerosols: in vivo SPECT compared with mathematical modeling.

W. Finlay, H. Chan, I. Gonda, 1996, Journal of applied physiology.

Home Management of Childhood Asthma Exacerbations

I. Amirav, P. Zuberbuhler, Telford Yeung, 2018, Pulmonary Therapy.

Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols

W. Finlay, K. Stapleton, P. Zuberbuhler, 1997 .

The Effect of Ambient Relative Humidity on Regional Dosages Delivered by a Jet Nebulizer

R. M. Prokop, W. Finlay, K. Stapleton, 1995 .

Low bone mineral density in cystic fibrosis patients.

N. Brown, P. Zuberbuhler, J. Tabak, 2002, Canadian journal of dietetic practice and research : a publication of Dietitians of Canada = Revue canadienne de la pratique et de la recherche en dietetique : une publication des Dietetistes du Canada.

Cost of Care for Individuals with Cystic Fibrosis: A Regression Approach to Determining the Impact of Recombinant Human DNase

Jeffrey A. Johnson, P. Jacobs, J. A. Johnson, 1999, Pharmacotherapy.

In vitro comparison of beclomethasone and salbutamol metered-dose inhaler aerosols inhaled during pediatric tidal breathing from four valved holding chambers.

W. Finlay, P. Zuberbuhler, 1998, Chest.

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

J. Rommens, P. Böelle, L. Strug, 2016, Human molecular genetics.

Variations in Predicted Regional Lung Deposition of Salbutamol Sulphate Between 19 Nebulizer Types

W. Finlay, K. Stapleton, P. Zuberbuhler, 1998 .

PREDICTING REGIONAL LUNG DOSAGES OF A NEBULIZED SUSPENSION: PULMICORT® (BUDESONIDE)

W. Finlay, K. Stapleton, P. Zuberbuhler, 1997 .

Errors in regional lung deposition predictions of nebulized salbutamol sulphate due to neglect or partial inclusion of hygroscopic effects

W. Finlay, K. Stapleton, P. Zuberbuhler, 1997 .

Body fat assessed from body density and estimated from skinfold thickness in normal children and children with cystic fibrosis.

H. Quinney, P. Zuberbuhler, P. Conger, 1988, The American journal of clinical nutrition.

Combined evaluation of circulating immune complexes and antibodies toPseudomonas aeruginosa as an immunologic profile in relation to pulmonary function in cystic fibrosis

J. Costerton, M. Dasgupta, N. Brown, 2004, Journal of Clinical Immunology.

Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients.

N. Brown, Y. K. Goh, P. Zuberbuhler, 1995, The American journal of clinical nutrition.

Particle size measurements for the space-chamber metered dose inhaler holding chamber compared with aerochamber and metered dose inhaler alone

M. Mandl, W. Finlay, P. Zuberbuhler, 1997 .

Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis

C. Castellani, F. Ratjen, P. Durie, 2019, BMC Pediatrics.

In vitro comparison of salbutamol hydrofluoroalkane (Airomir) metered dose inhaler aerosols inhaled during pediatric tidal breathing from five valved holding chambers.

W. Finlay, W H Finlay, P. Zuberbuhler, 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

J. Rommens, P. Böelle, L. Strug, 2016, Human molecular genetics.

Comparisons between inhaled fine particle fractions and lung dose for nebulized aerosols.

W. Finlay, K. Stapleton, P. Zuberbuhler, 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Prognostic implications of circulating immune complexes and Pseudomonas aeruginosa-specific antibodies in cystic fibrosis.

J. Costerton, M. Dasgupta, G. Döring, 1987, Journal of clinical & laboratory immunology.